"The American Diabetes Association [3], a leading patient health group, privately enlisted an Eli Lilly & Co. [4] executive to chart its growth strategy and write its slogan. The National Alliance on Mental Illness [5], an outspoken patient advocate, lobbies for treatment programs that also benefit its drug-company donors. ... Although patients seldom know it, many patient groups and drug companies maintain close, multimillion-dollar relationships while disclosing limited or no details about the ties," reports Thomas Ginsberg. In some cases, companies have "loaned" the services of their executives to advise or even lead patient groups. Ginsberg's investigation found that "the groups rarely disclose such ties when commenting or lobbying about donors' drugs. They also tend to be slower to publicize treatment problems than breakthroughs. And few openly questioned drug prices."